Aurora Oncology

Aurora Oncology is a pre-clinical, pre-revenue biotech advancing a novel, targeted approach to treating and diagnosing superficial bladder cancer. Its technology platform centers on EGFR-targeting, featuring a lead fusion toxin (DAB389EGF) with enhanced affinity and a complementary theranostic nanoparticle system for imaging and ablation. The company has secured significant non-dilutive funding through NIH SBIR grants and is affiliated with the Stanford and University of Colorado SPARK translational programs, positioning it to address a high-unmet-need market with outdated standard-of-care treatments.

EGFR-targeted platform comprising a high-affinity EGF-diphtheria toxin fusion protein for targeted cell killing and multifunctional gold nanoparticles for theranostic (imaging + ablation) applications. Both designed for intravesical delivery in bladder cancer.

Competition includes other companies developing intravesical therapies (e.g., gene therapies, immunotherapies) to replace or combine with BCG, as well as systemic therapies for advanced disease. Key differentiators for Aurora are the novel mechanism of its fusion toxin (binding-only, not inhibition) and its integrated theranostic approach for precision treatment.